Computerized results of Menopause Type^® Questionnaire:				Print This Page
Menopause Type^® Five
Menopause Type^® Five has symptoms that reveal decreased estradiol function, decreased testosterone function, but adequate progesterone function. Health risks associated with Menopause Type^® Five may include vulvar disorders, decreased muscle mass, depression, decreased mental function, osteoporosis and heart disease including angina pectoralis (chest pain). Since estradiol plays an important role in blood glucose metabolism, there is also increased risk of insulin resistance and blood sugar disorders. Risks associated with insulin resistance include increased risk of heart disease, diabetes and endometrial cancer.			See Pages 111-119
PROTOCOL: The following protocol provides women with Menopause Type^® 5 information on which nutritional and herbal formulations can support the normal function of hormone responsive tissues. Please review the Advanced Integrative Management of Menopause document for more detailed information.
Foundational Interventions:
Foundational interventions include lifestyle and dietary choices that support optimal hormone function. In addition, a high grade multiple vitamin mineral formulation rich in antioxidants and essential fatty acids rich in docosahexaenoic acid are required for optimal hormone function
Ultra Preventive® X V-Cap- A high grade multiple vitamin and mineral supplement with significant antioxidant support. Vitamins and minerals are cofactors required for every biochemical process in the human body, including the production and proper detoxification of hormones. Oxygen stress contributes to some of the pathophysiolgical effects of suboptimal menopause. These effects may be prevented and/or treated by improving the antioxidant defense of perimenopause, menopause, and postmenopausal women.
Opti DHA - An essential fatty acid rich in docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), with a high DHA:EPA ratio. The essential fatty acid DHA help maintain ideal cell membrane fluidity allowing optimal transport of molecules across the membrane, which is critical for hormone function, while EPA helps the body control inflammation.
Primary Endocrine Formulations :
Primary Endocrine Nutraceutical formulations should be used to support the function of hormone producing glands and hormone responsive tissues. The primary formulations that are appropriate to manage hormonal imbalances observed in Menopause Type^® Five include:
Estro-Mend^™ is a synergistic formulation of isoflavones, phytoestrogens and other herbs to naturally support hormonal balance by supporting the ideal function of estrogen responsive tissues as needed in Menopause Type^® Five. More Information Estro-Mend^™
Testo-Gain^™, a unique blend of phytoandrogens, adaptogens and other herbs to naturally support hormonal balance by supporting the ideal function of testosterone producing tissues and of testosterone responsive tissues as needed in Menopause Type^® Five. More Information on Testo-Gain^™
Please Find a Healthcare Professional in your area to customize these protocols.
Secondary Endocrine Formulations:
Since decreased thyroid function can adversely affect the function of other hormones, a nutraceutical formulation to support the function of the thyroid gland and the liver (which converts T4 to T3) and also supports the function and response of tissues that respond to thyroid hormones should be used if there are signs and symptoms of decreased thyroid function. As noted, there may be decreased blood glucose function in Menopause Type^® Five due to the primary hormone imbalances. Excessive body weight also increases the risk for decreased blood glucose function. A nutraceutical formulation to support healthy blood glucose function should be used if there are signs and symptoms of decreased blood sugar function
Thyro-Mend^™ is a synergistic combination of iodine containing seaweeds, and herbs which contain phytothyroidogenic, phyto-thyroid-receptor agonists, and other herbs designed to promote optimal function of thyroid hormones by maintaining the health of thyroid hormone producing tissues and by supporting the healthy function of tissues that respond to thyroid hormones. More information on Thyro-Mend^™
Glucobrium is a synergistic formulation of phytotherapeutic extracts which mimic and potentiate the actions of insulin and support healthy blood glucose function. More information on Glucobrium.
When to Consider Hormone Precursors & Bioidentical Hormone Replacement Therapy
Hormone precursors such as Pregnenolone 25 Mg Tab, DHEA 5 MG and 7-KETO may be used to support hormone production pathways that create testosterone and estrogens. They have mild hormone actions in and of themselves, and do not have the same risks that are associated with Hormone Replacement Therapies (HRT). Bioidentical Hormone Replacement Therapy (BHRT), while considered more appropriate than synthetic hormone therapies, does not support the hormone production pathways, but instead provides “replacement”, which may further diminish endogenous hormone production. Evaluation of hormone levels, use of hormone precursors as needed, and as a final course of action, the prescription of bioidentical hormone therapies should be considered only when restoration of normal function is not possible.
Also Review:
Protocols based on Menopause Primary Concern
Make the Right Choice
Work with a Healthcare Professional in your area: Find a healthcare professional in your area who has shown such commitment as to take an extensive course of study on menopause type^® management, including nutritional, herbal & natural hormone therapies. Please go to Find a Healthcare Professional .
How Your Menopause Type^® Was Calculated (www.YourMenopauseType.com/Questionnaire.html#Calculate)
♦These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Review Disclaimer & Legal (www.YourMenopauseType.com/Disclaimer)
YourMenopauseType.com, Inc. Copyright © & ® | Disclaimer and Legal | Contact Us
Home	Print This Page	Last update 03/18/07